Panorama® is a DNA screening test that can tell you important information about your pregnancy. You can find out if your baby is at risk for having Down syndrome or other chromosomal abnormalities. Panorama can also tell you the gender of your baby. Non-invasive and highly accurate, Panorama has the lowest false positive rate of any prenatal screening test for the commonly screened chromosomal abnormalities, trisomy’s 21, 18 and 13. And, Panorama can be done as early as nine weeks into your pregnancy using a simple blood draw.


The Horizon carrier screen is a simple test that looks at your genes to see if you are a carrier for specific autosomal recessive and X-linked genetic conditions. It is common for people to be carriers of at least one genetic condition. Carriers are usually healthy; however, they have a risk of passing on a genetic condition to their children. Horizon can provide valuable information to you about your carrier status before or during pregnancy. Horizon screens for up to conditions. You may have heard of some of the conditions including Cystic Fibrosis, Spinal Muscular Atrophy, Fragile X, or Duchenne Muscular Dystrophy. Many of the conditions included on the Horizon screen are early onset, while others may develop later in life.

Chromosome Study

Karyotyping is a test to examine chromosomes in a sample of cells. This test can help identify genetic problems as the cause of a disorder or disease.Karyotyping is a test to examine chromosomes in a sample of cells. This test can help identify genetic problems as the cause of a disorder or disease.The test can be performed on almost any tissue, including:

  • Amniotic fluid
  • Blood
  • Bone marrow
  • Tissue from the organ that develops during pregnancy to feed a growing baby

Paternity Testing

DNA paternity testing determines the biological father of a child. We all inherit our DNA from our biological parents — half from our mother, and half from our father. A DNA paternity test compares a child’s DNA pattern with that of an “alleged father” to determine if there is a match. When performed correctly in an experienced laboratory, it’s the most definitive proof of a biological relationship.


For couples who pursue in vitro fertilization (IVF), Spectrum PGS offers embryo screening to improve the chance of achieving a healthy pregnancy. PGS is used to identify embryo(s) that have extra or missing chromosomes, also called aneuploidy. Screening for the number of chromosomes allows for the selection and transfer of embryo(s) mostly likely to have  the correct chromosome number. These embryos are more likely to implant and are much less likely to miscarry.

while any couple can have an embryo with aneuploidy, couples at higher risk and couples who are considering single embryo transfer (SET) should ask their doctor about Spectrum.


Anora looks at tissue from a pregnancy loss (also called ‘products of conception’ or ‘POC’) to find out if a chromosome abnormality was the likely cause of the miscarriage. The results of Anora can reduce your emotional burden caused by a miscarriage by helping to explain why it occurred. It can also help identify if there is an increased chance for you to have another pregnancy with a chromosome problem.

Anora tests POC tissue on a Single Nucleotide Polymorphism (SNP) microarray looking for missing or extra chromosomes (called aneuploidy), missing or extra pieces of chromosomes (called deletions/duplications), and uniparental disomy (UPD) which is two copies of a chromosome from one parent and no copies from the other parent.

Cancer screening

Screening for mutation of genes that cause Breast cancers and Hereditary cancers with NGS technology. The patient could select breast and ovarian cancer or common cancer genes (up to 104 genes).

Next Generation Sequencing (NGS)

Whole Genome and Exome Sequencing using NGS have been widely accepted to speed up and reduce the cost of sequencing genomes for basic research as well as use of genomic data for a wide range of applications : genome wide association studies for complex diseases, variant calling to identify clinically actionable mutations and other specialized areas like identification of mutations that accumulate and give rise of tumor neo-antigens and shared antigens.